ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
ת»¯Ò½Ñ§ÒÔÒ©ÎïÑз¢Àú³ÌÖÐÉúÎï±ê¼ÇÎïΪ½¹µã£¬ÒÔ¾«×¼Ò½ÁÆÌá¸ßÒ©ÎïÑз¢ÁÙ´²Ó¦´ðÂÊΪĿµÄ£¬ÁýÕÖ´ÓÔçÆÚ°ÐµãÈ·ÈÏ¡ª¡ªÁÙ´²Ç°R&D ¡ª¡ªÁÙ´²I¡¢II¡¢IIIÆÚDevelopment£¬µ½ÉÏÊкóµÄÒ©Îï¼ì²â£¬Í¨¹ý²î±ð½×¶ÎµÄÑо¿ÊµÏÖÒ©ÎïÑз¢µÄ±Õ»·¡£
×ðÁú¿Ê±×ª»¯Ò½Ñ§Æ½Ì¨ÓµÓÐÂÄÀú¸»ºñµÄרҵ»¯ÊÖÒÕÍŶӣ¬´ÓÒ©Îï°ÐµãµÄ×÷ÓûúÖÆºÍÉúÎï±ê¼ÇÎïµÄÁÙ´²Ó¦Óóö·¢£¬ÒÔÉúÎï±ê¼ÇÎïµÄ·¢Ã÷ºÍÑé֤Ϊ»ù´¡£¬Á¬Ïµ¶àÖÖ²î±ðµÄÊÖÒÕÆ½Ì¨ºÍÏȽøµÄÒÇÆ÷£¬ ½¨ÉèÁ˶àÖÖÉúÎïÆÊÎöÒªÁ죬½µµÍÁËÒ©ÎïÑз¢µÄ±¾Ç®ºÍʱ¼ä£¬Îª²î±ðÀàÐ͵ÄÒ©Îï¡¢²î±ðÀàÐ͵ÄÒ©ÆóºÍ²î±ðÑз¢½×¶ÎµÄÏîÄ¿Ìṩ¶àÔª¸ßЧµÄЧÀÍ¡£
Ëæ×Å»ùÒò×éѧ¡¢ÂѰ×ÖÊ×éѧºÍ´úл×éѧµÈ¶à×éѧÆÊÎöÊÖÒÕÒ»Ö±µØÉú³¤£¬ÖÎÁÆ·½·¨ÒѾ´Ó¹Å°åС·Ö×ÓÀ©Õ¹µ½¶àëÄ¡¢ÂѰס¢¿¹Ìå¡¢»ùÒòÁÆ·¨¡¢Ï¸°ûÁÆ·¨µÈ¶àÖÖÐÂÐÍÊÖÒÕ¡£Ö»¹ÜÓÐÕâЩÐÂÊÖÒÕ£¬µ«ÈÔÓдó×Ú¼²²¡µÄÖ²¡Ôµ¹ÊÔÓÉ»¹ÎÞ·¨³¹µ×Ã÷È·¡£×ª»¯Ò½Ñ§½«ÉúÎïҽѧÊÓ²ìºÍÑо¿×ª»¯Îª¸ÄÉÆ¿µ½¡µÄ¸ÉÔ¤²½·¥µÄÀú³Ì£¬¼ÓËÙÁË»ù´¡Ñо¿¡¢ÐÂÒ©¿ª·¢µÄºÍÁÙ´²×ª»¯µÄÀú³Ì£¬³ÉΪ¾«×¼°ÐÏòÖÎÁƵļÓËÙÆ÷¡£×ª»¯Ò½Ñ§Ñо¿Ê¹ÓÃÖÖÖÖÑо¿ÊֶΣ¬È·¶¨°ÐµãÓë¼²²¡±¬·¢Éú³¤µÄ¹ØÏµ¡¢ÑéÖ¤ºÍ̽Ë÷Ò©ÎïµÄ×÷ÓûúÖÆ¡¢·¢Ã÷ÉúÎï±ê¼ÇÎï²¢¿ª·¢ÅãͬÕï¶Ï²úÆ·£¬ÒÔ¼°ÎªÁÙ´²Ñо¿¿ªÕ¹É¸Ñ¡×îºÏÊʵÄÈËȺºÍ˳Ӧ֢µÈ£¬´Ó¶øÌá¸ßÐÂÒ©Ñз¢Ð§ÂʺÍÀÖ³ÉÂÊ¡£
½«×ª»¯Ò½Ñ§Àï³Ì±®µþ¼Óµ½Ò©Î↑·¢½×¶Î[1]
ÉúÎï±ê¼ÇÎBiomarker£©Í¨³£ÊÇÖ¸Äܱ»¿Í¹ÛÕÉÁ¿ºÍÆÀ¼Û£¬·´Ó¦ÐÄÀí»ò²¡ÀíÀú³Ì£¬ÒÔ¼°¶Ô̻¶»òÖÎÁƸÉÔ¤²½·¥±¬·¢ÉúÎïѧЧӦµÄÖ¸±ê¡£ÉúÎï±ê¼ÇÎï¶àȪԴÓÚÈËÌå×éÖ¯»òÌåÒº£¬¿Éº¸ÇÐÄÀí¡¢Éú»¯¡¢ÃâÒß¡¢Ï¸°ûºÍ·Ö×ÓµÈˮƽµÄ¸Ä±ä¡£
ÉúÎï±ê¼ÇÎïµÄ¼ì²â¿ÉÆÕ±éµØÓ¦ÓÃÓ벡È˵Äɸ²é¡¢Õï¶Ï¡¢ÁÙ´²Ñо¿¡¢Ö¸µ¼ÓÃÒ©¡¢Ô¤ºóµÈÁìÓò¡£¿ÉÌá¸ß»ùÓÚ»ùÒò×éѧ¡¢ÂѰ××éѧ¡¢Ï¸°û×éѧ¡¢²¡Àí×éѧµÈ¶à×éѧµÄÉúÎï±ê¼ÇÎï·¢Ã÷¼°Ñé֤ЧÀÍ¡£ÎªÉúÎï±ê¼ÇÎïÑо¿Ìṩ¿ÆÑ§Ö§³Ö£¬¶à²ãÃæÖúÁ¦ÐÂÒ©Ñз¢ÁÙ´²ÊÔÑé¡£ÉúÎï±ê¼ÇÎï×÷Ϊ×îÖ±½Ó¿ìËÙÓÐÓõÄÕï¶ÏÊֶΣ¬ÆäɸѡÓë»ñµÃ¿ÉÔÚ¼²²¡Õï¶Ï¡¢Éú³¤¡¢ÖÎÁÆ¡¢ÒÔ¼°ÁÆÐ§¼à²âµÈ¶à¸ö·½ÃæÊ©Õ¹Ö÷ÒªµÄ×÷Óá£ÉúÎï±ê¼ÇÎïÓлùÓÚDNAµÄ¡¢ÓлùÓÚRNAµÄ¡¢ÉÐÓлùÓÚÂѰ×Öʵ쬲î±ðµÄ·Ö×ÓºÍÂѰ×ÐèÒª²î±ðµÄÊÖÒÕÆ½Ì¨¡£Ëæ×ŸßͨÁ¿»ùÒò×éѧ¡¢ÂѰ×ÖÊ×éѧµÈµÄһֱϣÍû£¬ÉúÎï±ê¼ÇÎï°üÀ¨µÄÖÖÀàÒ²Ô½À´Ô½¶à£¬ÀýÈçSNP¡¢ÍâÃÚÌå¡¢miRNA¡¢lncRNAµÈ¶¼±»ÁÐÈëÉúÎï±ê¼ÇÎïµÄÐÐÁС£ÏÖÔÚÒÑÓжàÖÖÊÖÒÕÆ½Ì¨±»Ó¦ÓÃÓÚÉúÎï±ê¼ÇÎïÑо¿£¬Èç°üÀ¨»ùÒò×éѧ¡¢ÂѰ×ÖÊ×éѧ¡¢ëÄ×éѧ¡¢´úл×éѧµÈÔÚÄÚµÄ×éѧƽ̨£¬ÒÔ¼°°üÀ¨ÄÉÃ×ÊÖÒÕ¡¢ÉúÎïÐÅϢѧ¡¢¿¹ÌåоƬ¡¢¸ßÄÚÔÚɸѡÊÖÒÕ¡¢ÎÞ±ê¼ÇÏ໥×÷ÓÃÆÊÎöÊÖÒյȶàÖÖÇ°ÑØÊÖÒÕÔÚÄÚµÄÊÖ¶ÎÓëÒªÁ죬¶¼Îª¿ìËÙ»ñµÃ¼°É¸Ñ¡ÉúÎï±ê¼ÇÎï´øÀ´Á˼«´óµÄ¿ÉÄÜ¡£
? Õï¶ÏÐÔÉúÎï±ê¼ÇÎÓÃÓÚ¼ì²â»òÈ·Èϼ²²¡×´Ì¬£¬»òʶ±ð²î±ð¼²²¡ÑÇÐÍ¡£
? Ô¤ºóÐÔÉúÎï±ê¼ÇÎ·´Ó¦¼²²¡Ô¤ºóÌØÕ÷¡¢¼²²¡¸´·¢»òÏ£ÍûΣº¦¡£
? Õ¹ÍûÐÔÉúÎï±ê¼ÇÎÓÃÓÚÕ¹Íû»¼Õß¶ÔijÖÖÖÎÁÆ»ò¸ÉÔ¤²½·¥¿ÉÄܱ¬·¢Ä³ÖÖÁÆÐ§Ó¦´ð¡£
? ҩЧѧÉúÎï±ê¼ÇÎ·´Ó¦»¼ÕßÔÚ½ÓÊÜÖÎÁƺ󱬷¢Ä³ÖÖÉúÎïѧӦ´ð¡£
? Çå¾²ÐÔÉúÎï±ê¼ÇÎÓÃҩǰ»òÓÃÒ©Àú³ÌÖмà²â´Ó¶ø×èÖ¹»ò½µµÍ»¼Õß±¬·¢²»Á¼·´Ó¦¡£
? ¼à²âÐÔÉúÎï±ê¼ÇÎ¼à²â¼²²¡×´Ì¬×ª±ä£¨È縴·¢µÈ£©¡£
? PD1/PD-L1
? ErbB2/HER2
? p-FGFR1/FGFR2/FGFR3¡¢p-ERK¡¢p-CREB¡¢p-AKT
? EGFR
? VEGF
? p53
? Cyclin D1
? COX-2
? Cytokeratin 7£¨CK7£©
? K-Ras
? SOX2
? MET
? Fas
? ER-¦Á
? Ki-67µÈ
WBC100 ÊÇÒ»ÖÖÐÂÐͿڷþÓÐÓõķÖ×Ó½º£¬¿ÉÑ¡ÔñÐԵؽµ½â c-Myc ÂѰ׶ø¶ÔÆäËûÂѰ×ÎÞ×÷ÓûîÐÔ£¬²¢ÓÐÓÃɱËÀc-Myc¹ý±í´ïµÄ°©Ï¸°û¡£SPRЧ¹ûÏÔʾ WBC100 Óë c-Myc ÂѰ×Á¬Ïµ£¬ÇÒ±£´æ¼ÁÁ¿ÒÀÀµÐÔ¡£´ËSPRʵÑéÕýÊÇͨ¹ý×ðÁú¿Ê±Ê¹ÓÃBiacore T200ÒÇÆ÷¾ÙÐеġ£
Surface plasmon resonance (SPR)[2]
? 8 needles and 16 flowcells, study 8 targets at the same time£»
? High-throughput, 500 compounds/day£»
? Fast detection speed£¬finish one affinity and kinetic test in 2-15 minutes.
A: Binding kinetics of different doses of Nivolumab with PD-1 (Biacore 8K)
B: Binding kinetics of different doses of Aflibercept with recombinant human VEGF (Biacore 8K)
×ðÁú¿Ê±ÉúÎïÆÊÎö²¿¿ÉÒÔΪ¿Í»§ÌṩС·Ö×ÓÒ©Îï¡¢´ó·Ö×ÓÉúÎïÖÆÆ·¡¢ÉúÎï±ê¼ÇÎïµÄɸѡÓ뿪·¢£¬ÒÔ¼°ÁÙ´²Ç°ºÍÁÙ´²½×¶ÎµÄÑо¿Ð§ÀÍ¡£¿ÉÒÔÌṩÇкÏFDA/NMPA GLPµÄÉúÎïÊÖÒÕÒ©ÎïÉúÎïÆÊÎöЧÀÍ£¬ÒÔÖ§³ÖÂѰ×Ò©Îï¡¢¿¹ÌåÒ©Îï¡¢ÒßÃç¡¢ÉúÎï±ê¼ÇÎϸ°ûºÍ»ùÒòÖÎÁÆÒ©ÎïµÄÔçÆÚ¿ª·¢£¬¼°ÆäÁÙ´²Ç°Ñо¿ºÍÁÙ´²Ñо¿¡£
? ÃâÒ߯ÊÎöÒªÁìµÄ¿ª·¢¼°ÒªÁìѧÑéÖ¤
? ÂѰס¢¿¹Ìå¡¢ADC¡¢¶àëÄÒ©Îï¡¢ºËËá¡¢ÒßÃ缰ϸ°ûÓë»ùÒòÖÎÁƲúÆ·µÈµÄÆÊÎö
? ÉúÎï±ê¼ÇÎïµÄɸѡ¡¢ÑéÖ¤ÓëÆÊÎö¡¢Ï¸°ûÒò×Ó¼ì²â
? ¿¹Ò©ÐÔ¿¹Ì壨ADA£©ÃâÒßÔÐÔÆÊÎö
? ÒßÃçµÄÃâÒßÔÐÔÆÊÎö
? ²¡¶¾µÄ»îÐÔÆÊÎö
? ÒßÃçµÄЧ¼Û²â¶¨
? ÁÙ´²ÑùÆ·ÉúÎïÆÊÎö
? Ö§³ÖPK Ò©´ú¶¯Á¦Ñ§¡¢TK ¶¾´ú¶¯Á¦Ñ§¡¢×éÖ¯ÂþÑÜÊÔÑé¡¢INDÉ걨
? ʵÑéÊÒʵÑéÖÜÈ«µÄÐÅÏ¢»¯ÖÎÀí£¬ÔËÓÃÑéÖ¤¹ýµÄʵÑéÊÒÐÅÏ¢ÖÎÀíϵͳ£¨Watson LIMS 7.2£©½¨ÉèÁËÍêÉÆµÄÑùÆ·ÖÎÀíÁ´ºÍʵÑéÊý¾ÝµÄ´¦Öóͷ£¡¢¸ú×ÙÓë´æ´¢Á´£»
? SensaTronicsÎÂ¶È¼à¿ØÏµÍ³£»
? ÑéÖ¤¹ýµÄWinNonlin Èí¼þÓÃÓÚÊý¾ÝÆÊÎö£»
? Êý¾Ý±»FDAºÍNMPA½ÓÊÜ£¬ÌṩÖÜÈ«ÇкÏFDA/NMPA/OECD GLP¹æ·¶ÒªÇóµÄÉúÎïÊÖÒÕÒ©ÎïÆÊÎöЧÀÍ£»
? ×ÔÁ¦µÄС·Ö×ÓÉúÎïÆÊÎöƽ̨ºÍÉúÎïÊÖÒÕÒ©ÆÊÎöƽ̨£»
?ÓµÓÐSpectraMaxM4/M5/i3x, MSD, Luminex, Biacore 8K, Envision,Gyrolab£¬ABI7500 qPCR¡¢ddPCR¡¢FACSµÈÈ«·½Î»¶à¹¦Ð§µÄÊÖÒÕÆ½Ì¨£»
? ÎÞаÔËÓÃELISA£¬ECL£¬IP£¬Co-IP£¬qPCR£¬ddPCR¡¢FACS£¬Elispot¡¢Ã¸Ñ§¡¢Cell-based µÈ¶àÖÖÒªÁ죬֧³ÖÇ°ÑØÉúÎïÒ©£¬ÖÖÀà°üÀ¨ÂѰס¢¿¹Ìå¡¢ADC¡¢¶àëÄ¡¢ºËËá¡¢ÒßÃ缰ϸ°û»ùÒòÖÎÁÆÒ©ÎïµÄÔçÆÚ¿ª·¢£¬¼°ÆäÁÙ´²Ç°Ñо¿ºÍÁÙ´²Ñо¿£»
? ¿ª·¢²¢ÑéÖ¤Õë¶Ô½ü°Ù¸ö²î±ð°Ðµã£¬ÈçCD-4£¬CTLA-4£¬PD-1£¬PD-L1¼°T-DM1ÀàËÆÎïADCµÈµÄÆÊÎöÒªÁ죬֧³ÖPK/TK/ÃâÒßÔÐÔ(Total ADA, Nab)/ÉúÎï±ê¼ÇÎï/ϸ°ûÒò×ÓÖÐÆÊÎö¡£
ÍùÆÚÎÄÕÂÖУ¬ÎÒÃÇͨ¹ý´ÓFACS ¼ì²â Cytokine ¼ì²âºÍϸ°û¹¦Ð§¼ì²â¶à¸öÏÖʵ°¸ÀýµÄ½Ç¶È³ö·¢£¬ÏêϸÏÈÈÝÁË¡°×ðÁú¿Ê±Á÷ʽϸ°ûÊÖÒÕÆ½Ì¨¡±£¨µã»÷Ïàʶ£©¡£×èÖ¹ÏÖÔÚ£¬×ðÁú¿Ê±³Ð½ÓµÄÁ÷ʽ¼ì²âÏîÄ¿ÒѾ½ü400Ï°üÀ¨Ï¸°ûÍâò¿¹Ô±í´ïµÄÁ÷ʽ¼ì²â£»Ï¸°ûÔöÖ³¡¢Ï¸°û·Ö½â¡¢Ï¸°ûµòÍöµÈµÄÁ÷ʽÆÊÎö£»¶¯ÎïÍâÖÜѪ¼°¸÷ÃâÒ߯÷¹Ù¼ì²â£»ÒÆÖ²ÁöÄ£×ÓÁ÷ʽ¼ì²âµÈ¡£×ðÁú¿Ê±Á÷ʽ¼ì²âÍŶӽ«Ã¿Ò»¸ö°¸ÀýµÄÌØµãÓë¶àÄêʵսÂÄÀúºÍÊÖÒÕ»ýÀÛÏàÁ¬Ïµ£¬ÉóÉ÷µØ½«ÓÅÖÊʵÑéЧ¹ûÌá½»µ½¿Í»§ÊÖÉÏ£¬Ò»Á¬ÖúÁ¦¿Í»§µÄÑз¢ÏîÄ¿»ñÅú¡£
ÃâÒß×黯£¬Ò²³ÆÃâÒß×éÖ¯»¯Ñ§ÊÖÒÕ(immunohistochemistry)»òÃâÒßϸ°û»¯Ñ§ÊÖÒÕ(immunocytochemistry)¡£ÊÇÖ¸Ó¦ÓÃÃâÒßѧ»ùÀ´Ô´Àí¼´¿¹ÔÓ뿹ÌåÌØÒìÐÔÁ¬ÏµµÄÔÀí£¬Í¨¹ý»¯Ñ§·´Ó¦Ê¹±ê¼Ç¿¹ÌåµÄÏÔÉ«¼ÁÏÔÉ«À´È·¶¨×é֯ϸ°ûÄÚ¿¹Ô£¨¶àëĺÍÂѰ×ÖÊ£©£¬¶ÔÆä¾ÙÐж¨Î»¡¢¶¨ÐÔ¼°Ïà¶Ô¶¨Á¿µÄÑо¿¡£Æ¾Ö¤¿¹Ô¿¹Ìå·´Ó¦ºÍ»¯Ñ§ÏÔÉ«µÄÔÀí£¬×éÖ¯ÇÐÆ¬»òϸ°ûÑù±¾ÖеĿ¹ÔÏȺÍÒ»¿¹Á¬Ïµ£¬ÔÙʹÓÃÒ»¿¹Óë¶þ¿¹·´Ó¦£¬DAB¾ÙÐÐÏÔÉ«£¬½ø¶ø¾ÙÐÐÆÊÎö¡£
? ×éÖ¯´¦Öóͷ£¡¢Àο¿¡¢ÇÐÆ¬
? ¿¹ÔÐÞ¸´
? ³ýÈ¥ÄÚÔ´ÐÔ¹ýÑõ»¯Îïø
? ¹Ø±Õ
? Ò»¿¹¡¢¶þ¿¹·õÓý
? ¼ì²â
? ¸´È¾
×éÖ¯Àο¿¿ÉÉúÑÄ¿¹Ô£¬±ÜÃâÊÕÂÞµÄ×éÖ¯×ÔÈܺͻµËÀ¡£×éÖ¯°üÂñ¿ÉÔÚÇÐÆ¬Àú³ÌÖжÔ×éÖ¯Ìṩ֧³Ö£¬Ê¹ÇÐÆ¬¸ü¼áʵ¡£
ʯÀ¯ÇÐÆ¬ | ±ù¶³ÇÐÆ¬ | |
Àο¿ | °üÂñǰ£º¼×È© | ÇÐÆ¬Ç°»òÇÐÆ¬ºó£º¼×È©¡¢¼×´¼¡¢ÒÒ´¼»ò±ûͪ |
ÇÐÆ¬ | ÇÐÆ¬»ú | ±ù¶³ÇÐÆ¬»ú |
Öü´æ | ÊÒÎÂÏÂÖü´æ¶àÄê | -80 ¡ãCÏÂÖü´æ1Äê £¨-190¡ãCÏÂÖü´æÊ±¼ä¸ü³¤£© |
ÓÅÊÆ | ÈÝÒײÙ×÷£¬²»»áËð»µÇÐÆ¬ | ? ±£´æÃ¸µÄ¹¦Ð§ºÍ¿¹ÔÐÔ ? ʵÑéÁ÷³Ì¼ò¶Ì£¨Í¨³£²»ÐèÒªÈß³¤µÄÀο¿°ì·¨£© |
¾ÖÏÞÐÔ | ? Ì«¹ýÀο¿»áÑÚÊο¹Ô±í룬½ø¶øÔöÌí¿¹ÔÐÞ¸´µÄÐèÇó ? ´¦Öóͷ£Ê±¼ä³¤£ºÔÚÌݶȾƾ«ºÍ¶þ¼×±½ÖÐÖð²½ÍÑË®£¬ÒÔ±ãÓÚʯÀ¯ÉøÍ¸¡£ | ? ÈôÊÇûÓпìËÙÀä¶³×éÖ¯¡±¿ÉÄÜ»áÐγɱù¾§£¬´Ó¶øÆÆËð×éÖ¯½á¹¹ ? ±ù¶³ÇÐÆ¬Í¨³£±ÈʯÀ¯ÇÐÆ¬ºñ£¬¿ÉÄܻᵼÖÂÇø·ÖÂʵ͡¢Í¼Ïñ²î ? ¿ÉÄÜÐèÒª×è¶ÏÄÚÔ´»îÐÔø¡£ |
ʯÀ¯ÇÐÆ¬ vs±ù¶³ÇÐÆ¬
¶Ô¼×È©Àο¿µÄ×éÖ¯ÇÐÆ¬¾ÙÐп¹ÔÐÞ¸´£¬ÒÔ̻¶¿¹Ôλµã£¬´Ó¶øÊ¹¿¹ÌåÁ¬Ïµ¡£
ÈÈÓÕµ¼µÄ¿¹Ô±íλÐÞ¸´ | ÂѰ×Ë®½âøÓÕµ¼µÄ¿¹Ô±íλÐÞ¸´ | |
ÓÅÊÆ | ¿¹Ô±íλµÄÐÞ¸´¸üÎÂ˳£¬²ÎÊý¸ü¿É¿Ø¡£ | ÊÊÓÃÓÚ½ÏÄÑÐÞ¸´µÄ¿¹Ô±íλ¡£ |
phÖµ | ͨ³£Ê¹ÓÃpH6µÄ»º³åÒº£¬µ«¼îÐÔ»º³åÒºÒ²ÔÚÆÕ±éʹÓᣱØÐèͨ¹ýʵÑéÈ·¶¨ | pHֵͨ³£Îª7.4¡£ |
ÎÂ¶È | Ô¼95¡ãC¡£ | ͨ³£Îª37¡ãC |
·õÓýʱ¼ä | 10-20·ÖÖÓ | 10-15·ÖÖÓ |
»º³åÒº×é·Ö | È¡¾öÓڰп¹ÔËùÐèµÄpH Öµ¡£³£ÓõĻº³åÒº°üÀ¨ÄûÃÊËáÄÆ¡¢EDTAºÍTris-EDTA | ø(ÈçθÂѰ×ø¡¢ÂѰ×øK »òÒÈÂѰ×ø)µÄÖÐÐÔ»º³åÒº¡£ |
×¢ÖØÊÂÏî | ΢²¨Â¯¼ÓÈÈ¿ÉÄܻᵼÖ¿¹ÔÐÞ¸´²»Ôȳơ£Ç¿ÁÒ»¶Ï²»áµ¼ÖÂÍÑÆ¬(×éÖ¯ÓëÔØ²£Æ¬ÊèÉ¢£©¡£ | øÐÞ¸´ÓÐʱ»áÆÆËðÇÐÆ¬µÄÐÎ̬- Ũ¶ÈºÍʱ¼äÐèÒªÓÅ»¯ |
¿¹ÔÐÞ¸´µÄÖ÷ÒªÒªÁì
ÓÃѪÇå»òBSA¹Ø±Õ£¬±ÜÃ⿹ÌåµÄ·ÇÌØÒìÐÔÁ¬Ïµ£¬²¢½µµÍÅä¾°ºÍDZÔڵļÙÑôÐÔЧ¹û¡£
? ÂѰ׹رգºÊ¹ÓÃѪÇå»òBSA ¾ÙÐйرչØÓÚ±ÜÃ⿹ÌåÓë×éÖ¯»òFc ÊÜÌ壨Ó뿹Ìåºã¶¨Çø£¨Fc£©Á¬ÏµµÄÊÜÌ壩±¬·¢·ÇÌØÒìÐÔÁ¬ÏµÖÁ¹ØÖ÷Òª¡£¶þ¿¹ÖÖÊôȪԴµÄѪÇåÊǺܺõĹرÕÊÔ¼Á¡£Ê¹ÓÃţѪÇå°×ÂѰף¨BSA£©»òÀÒÂѰף¬¿ÉÓÃÓÚ×è¶Ï·ÇÌØÒìÐÔ¿¹ÌåÁ¬Ïµ¡£
? ÉúÎïËØ¹Ø±Õ£ºÔÚʹÓûùÓÚÇ׺ÍËØ/ÉúÎïËØµÄ¼ì²âϵͳʱ£¬×è¶ÏÄÚÔ´ÐÔÉúÎïËØ£¬ÓÉÓÚÄÚÔ´ÐÔÉúÎïËØ±£´æÓÚÐí¶à×éÖ¯ÖУ¬ÌØÊâÊÇÉöÔࡢƢÔà¡¢¸ÎÔàºÍ´óÄÔÖС£ÓÃÇ׺ÍËØÓë×éÖ¯·õÓý£¬×è¶ÏÄÚÔ´ÉúÎïËØ£¬È»ºóÓÃÍâÔ´ÉúÎïËØ·õÓý£¬ÒÔ×è¶ÏÇ׺ÍËØ·Ö×ÓÉÏÌØÁíÍâÉúÎïËØÁ¬ÏµÎ»µã¡£
ÓÃѪÇå»òBSA¹Ø±Õ£¬±ÜÃ⿹ÌåµÄ·ÇÌØÒìÐÔÁ¬Ïµ£¬²¢½µµÍÅä¾°ºÍDZÔڵļÙÑôÐÔЧ¹û¡£
? øÏÔÉ«·¨£ºÏÔÉ«¼ì²âʹÓÃøÄܹ»´ß»¯¿ÉÈÜÐÔµ×Îﱬ·¢ÓÐÉ«³Áµí¡£ÕâЩøͨ³£Å¼ÁªÔÚ¶þ¿¹ÉÏ£¬Ò²¿ÉÒÔżÁªÔÚÒ»¿¹ÉÏÓÃÓÚÖ±½Ó¼ì²â¡£×î³£ÓõÄøÓÐHRP ºÍAP£¬Ç°Õß½«DAB ת»¯³Éרɫ²úÆ·£¬ºóÕß½«3-°±»ù-9-ÒÒ»ùßÇßò (AEC) ת»¯³ÉºìÉ«²úÆ·¡£ÏÔÉ«¼ì²âͨ³£±ÈÓ«¹â¼ì²â¸üѸËÙ¡£±ðµÄ£¬²î±ðÓÚÓ«¹âȾÁÏ£¬ÓÐÉ«³ÁµíÎïÓйâÎȹÌÐÔ£¬Òò´ËȾɫÇÐÆ¬Äܹ»ÉúÑĶàÄê¡£Ó«¹â¼ì²âÐèҪʹÓÃרҵӫÏÊÃ÷΢¾µºÍÂË¹âÆ¬£¬ÏÔÉ«¼ì²â½öÐèʹÓñê×¼ÏÔ΢¾µ¡£È»¶ø£¬ÏÔÉ«¼ì²âµÄ·õÓýºÍ¹Ø±Õ°ì·¨±ÈÓ«¹â·¨¸ü¶à£¬Ê±¼äÒ²¸ü³¤¡£
? Ó«¹â·¨£ºÓ«¹â¼ì²â£¨ÃâÒßÓ«¹â£©ÊÇ»ùÓÚÓ«¹â»ùÍű»Ìض¨²¨³¤µÄ¹âÒý·¢ºó·¢É䲨³¤½Ï³¤µÄÓ«¹âµÄÌØÕ÷¡£Ó«¹â¼ì²â¾³£ÓÃÓÚÐèҪͬʱ¼ì²â¶àÖÖ¿¹ÔµÄÇéÐΡ£Ó«¹âȾÁÏ¿ÉÒÔÓëÒ»¿¹»ò¶þ¿¹Ö±½ÓżÁª£¬Ò²¿ÉÓëÁ´Ã¹ËØÇ׺ÍËØÅ¼Áª¡£
ÒÇÆ÷×°±¸£¨²¿·Ö¾ÙÀý£©
IHC Analysis of the expression of a)PD-L1 from lung adenocarcinoma[3]; b)Ki-67 from periampullary tumors[4]; c)Her2 from lung tumor[5]; d)CD31 from human gastric adenocarcinoma[6]; e)CD163 (M2 TAM marker) from oral squamous cell carcinoma (OSCC)[7]; f)FoxP3 from human glioblastoma[8].
»ùÓÚ»ùÒò×éѧ¡¢ÂѰ××éѧ¡¢Ï¸°û×éѧ¼°²¡Àí×éѧµÈ×ÛºÏÐÔת»¯Ò½Ñ§Æ½Ì¨£»¸ßÖÊÁ¿µÄÑз¢ÖÎÀíÍŶӣ»×ðÁú¿Ê±×ª»¯Ò½Ñ§Æ½Ì¨ÖÂÁ¦ÓÚΪȫÇòÏàÖúͬ°éÌṩȫ·½Î»ÉúÎï±ê¼ÇÎï·¢Ã÷¡¢°ÐµãÑéÖ¤¡¢ÅãͬÕï¶Ï¿ª·¢ÓëÉÌÒµ»¯¼ì²âµÈÒ»Ì廯½â¾ö¼Æ»®¡£
? ÒÔELISA¡¢ECL£¨MSD), SIMOA£¨HD-X), Biacore 8K ÊÖÒÕ¹¹½¨µÄµÄÂѰ×ÖÊÏ໥×÷Óã¬ÂѰ×ˮһÉúÎï±ê¼ÇÎïÆ½Ì¨£»
? ÒÔÁ÷ʽϸ°ûÊõ£¨BD Symphony A3£¬BD Fortesssa, Beckman CytoFLEX S£©ÎªÖ÷¹¹½¨µÄϸ°ûˮһÉúÎï±ê¼ÇÎïÆ½Ì¨£»
? ÒÔÓ«¹â¶¨Á¿PCRÊÖÒÕ¹¹½¨µÄ¶àÖØºËËáˮһÉúÎï±ê¼ÇÎïÆ½Ì¨£»
? ÃâÒß×黯£¨TAMs-IHC£¬FISH£©ÊÖÒÕ¹¹½¨µÄ²¡ÀíˮһÉúÎï±ê¼ÇÎïÆ½Ì¨µÈ£»
ÖÂÁ¦ÓÚ½â¾öÁ¢ÒìÒ©ÎïµÄÑоÙʵ㣬ÖúÁ¦¾«×¼Ò½ÁÆ£¡
ÎÒÃǺÜÐÒÔ˵ØÉúÑÄÔÚÒ»¸öÉúÎïҽѧ¿ÆÑ§¿´ËÆÎÞÏÞ¿ÉÄܵÄʱ´ú¡£ÔÚÕâ¸öʱ´ú£¬Ñо¿µÄÎÊÌâ²»ÔÙÖ÷ÒªÊÜÊÖÒÕÄÜÁ¦µÄÏÞÖÆ¡£×ª»¯Ò½Ñ§µÄʵÏÖÐèҪͬÑùÒ»Á¬´óµ¨µÄÔ¸¾°ºÍÖ´ÐС£ÔÚÒÑÍù¼¸Ê®Ä꣬ת»¯Ò½Ñ§È¡µÃÁËÏÔÖøÇ°½ø£¬Î´À´×ª»¯Ò½Ñ§½«¼ÌÐøÉú³¤£¬²¢¸ü¿ì¡¢¸ü¸ßЧµØÎª¸ü¶à»¼ÕßÌṩ¸ü¶àÖÎÁƵĿÉÄÜÐÔ£¡
[1] Hugues Dolgos, et al. Translational Medicine Guide transforms drug development processes: the recent Merck experience. Drug Discov Today. 2016 Mar;21(3):517-26. doi: 10.1016/j.drudis.2016.01.003.
[2] Ying Xu, et al. A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors. Adv Sci (Weinh). 2022 Mar;9(8):e2104344. doi: 10.1002/advs.202104344.
[3] Jonas J Heymann, et al. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937.
[4] Mark M Aloysius, et al. Predictive value of tumor proliferative indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays. World J Surg. 2010 Sep;34(9):2115-21. doi: 10.1007/s00268-010-0681-3.
[5] Montse Verdu, et al. Cross-reactivity of EGFR mutation-specific immunohistochemistry assay in HER2-positive tumors. Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):565-70.
[6] Qingling Wang, et al. EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner. Oncol Lett. 2018 Aug;16(2):1565-1570. doi: 10.3892/ol.2018.8869.
[7] Faustino J Su¨¢rez-S¨¢nchez, et al. Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression. Cancers (Basel) (IF: 6.13; Q1). 2020 Jul 2;12(7):1764. doi: 10.3390/cancers12071764.
[8] Qi Yue, et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol. 2014 Jan;116(2):251-9. doi: 10.1007/s11060-013-1314-0. Epub 2013 Nov 26.[9] Christopher P Austin.Opportunities and challenges in translational science. Clin Transl Sci. 2021 Sep;14(5):1629-1647. doi: 10.1111/cts.13055.